CPRX Relative Valuation
CPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CPRX is overvalued; if below, it's undervalued.
Historical Valuation
Catalyst Pharmaceuticals Inc (CPRX) is now in the Fair zone, suggesting that its current forward PE ratio of 15.36 is considered Fairly compared with the five-year average of 13.69. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 13.82 to 23.95 according to relative valuation methord.
Relative Value
Fair Zone
13.82-23.95
Current Price：21.81
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.32
P/B
Median3y
4.33
Median5y
3.82
10.04
FCF Yield
Median3y
3.62
Median5y
6.03
Competitors Valuation Multiple
The average P/S ratio for CPRX's competitors is 46.16, providing a benchmark for relative valuation. Catalyst Pharmaceuticals Inc Corp (CPRX) exhibits a P/S ratio of 4.79, which is -89.61% above the industry average. Given its robust revenue growth of 43.56%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Catalyst Pharmaceuticals Inc (CPRX) currently overvalued or undervalued?
What is Catalyst Pharmaceuticals Inc (CPRX) fair value?
How does CPRX's valuation metrics compare to the industry average?
What is the current P/B ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Jul 13 2025?
What is the current FCF Yield for Catalyst Pharmaceuticals Inc (CPRX) as of Jul 13 2025?
What is the current Forward P/E ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Jul 13 2025?